cache

Home cache
  • Next Post
  • Previous Post

cache

David Dornan, PhD

/ Uncategorized

Share the Post

About the Author

Related Posts

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
nab-Sirolimus in Patients with Malignant PEComa Previously Treated With mTOR Inhibitors: Emerging Experience From An Expanded Access Program
Read More
Bryan Ball
Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT

Comments

Comments are closed.

  • Next Post
  • Previous Post